Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion official investor newsroom · 行业原文收录 · 来源发布:Thu Oct 15 2026 12:45:47 GMT+0000 (Coordinated Universal Time) · 本站收录:Thu Oct 15 2026 13:07:49 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration October 15, 2026 at 8:45 AM EDT PDF Version Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT , Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion
以上为带出处的原文节选,完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。